Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,082 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up.
van Dalen A, Favier J, Hallensleben E, Burges A, Stieber P, de Bruijn HW, Fink D, Ferrero A, McGing P, Harlozinska A, Kainz Ch, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R, Goike H. van Dalen A, et al. Among authors: fink d. Eur J Gynaecol Oncol. 2009;30(6):609-15. Eur J Gynaecol Oncol. 2009. PMID: 20099488
Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
van Dalen A, Favier J, Burges A, Hasholzner U, de Bruijn HW, Dobler-Girdziunaite D, Dombi VH, Fink D, Giai M, McGing P, Harlozinska A, Kainz C, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R. van Dalen A, et al. Among authors: fink d. Gynecol Oncol. 2000 Dec;79(3):444-50. doi: 10.1006/gyno.2000.5982. Gynecol Oncol. 2000. PMID: 11104617 Clinical Trial.
Serum levels of CA 125 and TPS during treatment of ovarian cancer.
Van Dalen A, Favier J, Baumgartner L, Hasholzner U, De Bruijn H, Dobbler D, Dombi VH, Fink D, Giai M, McGing P, Harlozinska A, Kainz C, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R. Van Dalen A, et al. Among authors: fink d. Anticancer Res. 2000 Nov-Dec;20(6D):5107-8. Anticancer Res. 2000. PMID: 11326677
Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis.
Harter P, Hahmann M, Lueck HJ, Poelcher M, Wimberger P, Ortmann O, Canzler U, Richter B, Wagner U, Hasenburg A, Burges A, Loibl S, Meier W, Huober J, Fink D, Schroeder W, Muenstedt K, Schmalfeldt B, Emons G, du Bois A. Harter P, et al. Among authors: fink d. Ann Surg Oncol. 2009 May;16(5):1324-30. doi: 10.1245/s10434-009-0357-0. Epub 2009 Feb 19. Ann Surg Oncol. 2009. PMID: 19225844
The role of surgery in recurrent ovarian cancer.
Pfisterer J, Harter P, Canzler U, Richter B, Jackisch C, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, Bois A; AGO Ovarian Committee; AGO Ovarian Cancer Study Group (AGO-OVAR). Pfisterer J, et al. Among authors: fink d. Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:195-8. doi: 10.1111/j.1525-1438.2005.00430.x. Int J Gynecol Cancer. 2005. PMID: 16343230 Free article.
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. Perren TJ, et al. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. N Engl J Med. 2011. PMID: 22204725 Free article. Clinical Trial.
1,082 results